Effects of Statin Therapy on Arrhythmic Events and Survival in Patients With Nonischemic Dilated Cardiomyopathy

Journal of the American College of Cardiology

Volumn 48, Issue 6, 2006, Pages 1228-1233

  Goldberger, Jeffrey J ^a   Subacius, Haris ^a   Schaechter, Andi ^a   Howard, Adam ^a   Berger, Ronald ^b   Shalaby, Alaa ^c   Levine, Joseph ^d   Kadish, Alan H ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d ST FRANCIS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DISEASE ASSOCIATION; FEMALE; HEART ARREST; HEART ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; RISK REDUCTION; SUDDEN DEATH; SURVIVAL;

AGED; ARRHYTHMIA; CARDIOMYOPATHY, DILATED; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 33748572257     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.05.053     Document Type: Article

References (21)

1. Young-Xu Y., Jabbour S., Goldberg R., et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92 (2003) 1379-1383
2. Shiroshita-Takeshita A., Schram G., Lavoie J., and Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110 (2004) 2313-2319
3. Kumagai K., Nakashima H., and Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 62 (2004) 105-111
4. Laufs U., Wassmann S., Schackmann S., Heeschen C., Bohm M., and Nickenig G. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol 93 (2004) 103-108
5. Node K., Fujita M., Kitakaze M., Hori M., and Liao J. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
6. Sola S., Mir M., Lerakis S., Tandon N., and Khan B. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47 (2006) 332-337
7. DeSutter J., Tavernier R., DeBuyzere M., Jordaens L., and DeBacker G. Lipid lowering drugs and recurrences of the life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 36 (2000) 766-772
8. Chiu J., Abdelhadi R., Chung M., et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol 95 (2005) 490-491
9. Mitchell L., Powell J., Gillis A., Kehl V., Hallstrom A., and AVID Investigators. Are lipid-lowering drugs also antiarrhythmic drugs?. An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 42 (2003) 81-87
10. Horwich T., MacLellan W., and Fonarow G. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 43 (2004) 642-648
11. Kadish A., Dyer A., Daubert J., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 (2004) 2151-2158
12. Epstein A., Carlson M., Fogoros R., Higgins S., and Venditti F. Classification of death in antiarrhythmia trials. J Am Coll Cardiol 27 (1996) 433-442
13. Bleske B., Nicklas J., Bard R., et al. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 47 (2006) 338-341
14. Rauchhaus M., Clark A., Doehner W., et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 42 (2003) 1933-1940
15. Horwich T., Hamilton M., and Maclellan W. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 8 (2002) 216-4
16. Mozaffarian D., Nye R., and Levy W. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 93 (2004) 1124-1129
17. Kjekshus J., Pedersen T., Olsson A., Faergeman O., and Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Am Coll Cardiol 3 (1997) 249-254
18. Aronow W., and Ahn C. Frequency of congestive heart failure in older person with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 90 (2002) 147-149
19. Ellenbogen K., Levine J., Berger R., et al. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?. Circulation 113 (2006) 776-782
20. Uretsky B., Thygesen K., Armstrong P., et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the Assessment of Treatment with Lisinopril And Survival (ATLAS) trial. Circulation 102 (2000) 611-616
21. Pham M., Oka R., and Giacomini J. Statin therapy in heart failure. Curr Opin Lipidol 16 (2005) 630-634